Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
about
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesMolecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimusAntitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsLenvatinib for Anaplastic Thyroid Cancer.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis.Lenvatinib: first global approval.Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?Lenvatinib: A Review in Refractory Thyroid Cancer.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Efficacy of lenvatinib in treating thyroid cancer.Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.Angiogenesis inhibitors in early development for gastric cancer.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.Lenvatinib in Advanced Hepatocellular Carcinoma.Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.Prolonged duration of response in lenvatinib responders with thyroid cancer.Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
P2860
Q26751274-E486D58B-FA23-450C-A195-9E93C2DEB256Q26766689-A9562882-F5BC-4D36-B39D-5F1EF75FA4A1Q30249385-17A999DB-5705-4C7C-99A7-AAC6B7F07C95Q33427289-2CF86ACD-1E56-4A57-B676-21701A0A0D9CQ33607412-F4F36FEC-C5EA-456D-A4A3-188D02C1A823Q34253418-DA95A483-67EE-41BF-AE8D-A33A38194BFEQ37672425-4F002423-139E-4741-84AC-506BA018F60BQ37710134-5A7682DE-0484-4506-A415-374D67D95C7FQ37723370-E8374C40-7CFB-48DF-9308-43916986FF0DQ37744890-628EA65B-4775-47B3-8F64-79947BC537C8Q38385844-90C88086-F6ED-47C0-9955-6707FD80B3FAQ38702994-C3D07264-09DC-4FEC-BA21-BE31163828DAQ38729953-3CA37870-B472-4E04-8776-B290613A2926Q38826507-9D9DECC2-6350-48D2-8E4A-13CCF7F5F7D2Q38843403-346D6C92-A643-44E9-82CB-58F7540B21AFQ39706220-ACA72349-7996-48BA-A2C3-E4247FB6018FQ46573222-4E8FDB84-3D1E-44F3-8DDE-617A716AAFC0Q47144667-77B42286-8D65-4E74-B5F0-B7287746A355Q47996955-D3E53580-335E-423B-B558-BE5C69EE1C83Q49544357-6A2CBD6D-6767-4E56-B9AF-82D468EB548BQ49884642-19800A38-4AA0-4B12-B63B-2602E23FC36FQ50912525-22216271-4BC2-43F4-98B6-8B32B568E4C6Q52682465-F2AB1A6C-63AF-49FB-9FEE-3ABBBF4834BEQ52684456-22D9FBAD-344D-4F94-A7D3-04DD0DB92571Q53520555-DAE64378-9356-414F-8208-08FD8EA18492Q54111915-93039049-FB2C-47CF-99EE-3DFAF4FA3344Q54979598-C24110EA-AF30-47BC-B833-14DCA9D7FAE2Q55413273-7904EE09-E736-486B-9EFE-5C04625E2110Q57041735-C771EB14-715F-4FD3-8CB4-F62485746CFDQ57809492-E4F183A3-27AF-4868-B215-C94FC44DE6E7
P2860
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@ast
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@en
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@nl
type
label
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@ast
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@en
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@nl
prefLabel
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@ast
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@en
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@nl
P2093
P2860
P356
P1433
P1476
Lenvatinib, an angiogenesis in ...... density and pericyte coverage.
@en
P2093
Akihiko Tsuruoka
Atsumi Yamaguchi
Fusayo Mimura
Hiroshi Obaishi
Jun-Ichi Kamata
Junji Matsui
Katsuji Nakamura
Kazuki Miyazaki
Keiko Takahashi
Ken-Ichi Nomoto
P2860
P2888
P356
10.1186/2045-824X-6-18
P577
2014-09-06T00:00:00Z
P6179
1021771246